Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$25.89
▼ $0.49 (-1.9%)
Market data updated: 09/24 06:11 PM
Fundamentals updated: 09/24/2026
News analyzed: 09/24/2026
Market Cap
$3.25B
Day Range
$25.19 - $26.68
52-Week Range
$16.57 - $31.77
Beta
—
Next Earnings
26.10.2026
Support
$23.10
Resistance
$29.24
ARQT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+49.7% (1Y)
Strengths: 16/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 91.3%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$1.78 vs. price $25.89 (-106.9%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
58
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $25.89
Evidence: FOMO score jumped from 2 to 32 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
38
Momentum
74
Risk
48
Sentiment
62
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Arcutis Biotherapeutics has centered on its strategic growth and investor engagement. The company announced inducement grants of restricted stock units to 11 new hires under Nasdaq rules, signaling expansion. Arcutis also highlighted its upcoming participation in the *Morgan Stanley Global Healthcare Conference*, reinforcing its focus on dermatology innovations. Additionally, the firm raised its 2026 revenue guidance due to strong momentum with its lead product, Zoryve, particularly in younger patient segments, while facing valuation scrutiny amid recent stock volatility.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Arcutis Biotherapeutics, Inc.. News trend score: 62. Reason: 7 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
27
🎯 Conviction (vs. Emotion)
45
Psychology
54
Fundamentals
35
Technical
74
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-4%
Market Narrative
56
Fundamental Reality
45
Narrative Gap
+11
🧠 StockIQ Psychologist
The market behavior for ARQT suggests a dominant anchoring bias, where traders may be fixated on the recent support level (2.9% away), despite weak momentum and muted volume. The narrative gap (-19) further implies a disconnect between market sentiment (26) and observable fundamentals (45), reinforcing a potential reliance on past price anchors. While panic selling (32) is present, it’s tempered by low volatility, suggesting hesitation rather than outright capitulation. The key open question is whether traders will break free from the support anchor or if external catalysts could shift the balance toward risk-off behavior.
Updated: 09/06/2026, 06:44 PM
What could change this?
👥 What the crowd believes
"Arcutis raises its 2026 revenue guidance as Zoryve gains momentum"
"Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference"
"Arcutis Biotherapeutics Stock Performance Snapshot... stock down about 12% over the past month"
🧠 Market Brain events driving this
📈 6D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 91/100
🔴 Weakest match
Samuel Armstrong Nelson — 40/100
Peter Lynch
One Up on Wall Street (1989)
🟢 91
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 91
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 80
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 66
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 65
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 64
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 55
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 54
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 51
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 51
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 50
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 47
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 42
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 40
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 284 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
90.2%
Operating Margin
-3.3%
Net Margin
-4.3%
EBITDA Margin
-3.3%
ROE
-8.5%
ROA
-3.7%
ROIC
—
EPS
-$0.13
Cash
$42.91M
Total Debt
$108.96M
Current Ratio
3.17
Debt/Equity
0.58
How is Fair Value calculated? →
Current Price
$25.89
Estimated Fair Value (DCF)
-$1.78
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-106.9%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-7.89M | $-7.24M |
| 2 | 19.4% | $-9.42M | $-7.93M |
| 3 | 13.8% | $-10.71M | $-8.27M |
| 4 | 8.1% | $-11.58M | $-8.21M |
| 5 | 2.5% | $-11.87M | $-7.72M |
Base FCF (last actual year)
$-6.31M
Terminal Value
$-187.21M
Present Value of Terminal Value
$-121.67M
Enterprise Value
$-161.03M
Net Debt
$66.05M
Equity Value
$-227.08M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.49
Tangible Book Value per Share (Tangible NAV)
$1.37
Sentiment based on basic keywords (not AI) — 7 positive, 8 neutral, 5 negative out of the last 20 articles.
Yahoo · 21.9.2026
Insider Monkey · 21.9.2026
Yahoo · 21.9.2026
Zacks · 21.9.2026
ChartMill · 21.9.2026
ChartMill · 19.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Zacks · 17.9.2026
Yahoo · 17.9.2026
TIKR · 17.9.2026
SeekingAlpha · 16.9.2026
ChartMill · 7.9.2026
PR Newswire · 4.9.2026
Yahoo · 4.9.2026
GlobeNewswire · 4.9.2026
Yahoo · 4.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 28.8.2026
Arcutis Biotherapeutics, Inc. (ARQT) currently has a StockIQ AI score of 58/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ARQT currently scores 58/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ARQT's estimated fair value is -$1.78, which is 106.9% below the current price of $25.89. This is one valuation model among several signals in the fair-value category, not a price target.
ARQT's technical score is 74/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 91.3%; Earnings per share (EPS) growth: 88.8%; Free cash flow growth: 94.4%.
Based on the real signals StockIQ computed: Estimated fair value: -$1.78 vs. price $25.89 (-106.9%); Operating margin: -3.3% (negative); Net margin: -4.3% (negative).
StockIQ has no recorded dividend payment history for ARQT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Matsuda Masaru | Open Market Sale | 16.9.2026 | 3,674 | -3,674 | $25.00 |
| Welgus Howard G. | Exercise of Derivative Securities | 15.9.2026 | 822 | -822 | — |
| Welgus Howard G. | Exercise of Derivative Securities | 15.9.2026 | 822 | +822 | $6.52 |
| Welgus Howard G. | Open Market Sale | 15.9.2026 | 4,730 | -4,730 | $24.18 |
| Welgus Howard G. | Exercise of Derivative Securities | 15.9.2026 | 2,255 | -2,255 | — |
| Welgus Howard G. | Exercise of Derivative Securities | 15.9.2026 | 2,255 | +2,255 | $8.63 |
| Welgus Howard G. | Exercise of Derivative Securities | 15.9.2026 | 1,019 | +1,019 | $7.51 |
| Welgus Howard G. | Exercise of Derivative Securities | 15.9.2026 | 1,019 | -1,019 | — |
| Matsuda Masaru | Open Market Sale | 8.9.2026 | 9,989 | -9,989 | $25.03 |
| Curran Terrie | Open Market Sale | 27.8.2026 | 23,526 | -11,148 | $25.03 |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 34,674 | +11,148 | $7.51 |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 50,578 | +27,052 | $8.63 |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 0 | -11,148 | — |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 27,052 | +27,052 | $8.63 |
| Curran Terrie | Open Market Sale | 27.8.2026 | 11,148 | -11,148 | $25.03 |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 11,148 | -11,148 | — |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 27,052 | -27,052 | — |
| Curran Terrie | Open Market Sale | 27.8.2026 | 27,052 | -27,052 | $25.03 |
| Curran Terrie | Exercise of Derivative Securities | 27.8.2026 | 11,148 | +11,148 | $7.51 |
| Curran Terrie | Exercise of Derivative Securities | 20.8.2026 | 11,148 | -1,072 | — |
| Curran Terrie | Exercise of Derivative Securities | 20.8.2026 | 24,598 | +1,072 | $7.51 |
| Curran Terrie | Open Market Sale | 20.8.2026 | 23,526 | -1,072 | $26.04 |
| Curran Terrie | Exercise of Derivative Securities | 20.8.2026 | 1,072 | -1,072 | — |
| Curran Terrie | Exercise of Derivative Securities | 20.8.2026 | 1,072 | +1,072 | $7.51 |
| Curran Terrie | Open Market Sale | 20.8.2026 | 1,072 | -1,072 | $26.04 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
16,557,048 shares short as of 2026-08-31 · vs. 12,686,384 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
68.6% of trading volume this week was short selling, vs. 57.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology